Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus chemoradiation for conversion therapy of locally nonresectable ESCC
NCT05394415Phase 2Unknown
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- May 2022
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05394415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394415.